Abstract Number: 19L • 2016 ACR/ARHP Annual Meeting
Biosimilar Infliximab (CT-P13) Is Not Inferior to Originator Infliximab: Results from a 52-Week Randomized Switch Trial in Norway
Background/Purpose: TNF-inhibitors (TNFi) have improved treatment of spondyloarthritis (SpA), rheumatoid arthritis (RA), psoriatic arthritis (PsA), Crohn’s disease (CD), ulcerative colitis (UC), and chronic plaque…Abstract Number: 627 • 2016 ACR/ARHP Annual Meeting
Clinical and Immunogenicity Outcomes after Switching Treatment from Innovator Infliximab to Biosimilar Infliximab in Rheumatic Diseases in Daily Clinical Practice
Background/Purpose: Biosimilar infliximab is registered in Europe for the same therapeutic indications as innovator infliximab. In 2015, four rheumatology departments in the Netherlands decided to…Abstract Number: 630 • 2016 ACR/ARHP Annual Meeting
Strategies for Biological Drug Quantification in Biological Drug Immune Responses
Background/Purpose: The development of the biological DMARDs has benefitted patients, who previously had no treatment options. Currently no method for stratifying patients to these drugs…Abstract Number: 689 • 2016 ACR/ARHP Annual Meeting
Relationship Between Infliximab Serum Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis
Background/Purpose: Tumour necrosis factor alpha inhibitors are effective in reducing inflammation in rheumatic diseases while increasing the risk of infections. We aimed to study the…Abstract Number: 1122 • 2016 ACR/ARHP Annual Meeting
Infliximab Suppresses the Monocyte Chemotaxis in Human TNF-Transgenic Mice
Background/Purpose: Macrophages in rheumatoid arthritis (RA) synovium produce high levels of inflammatory cytokines/chemokines and play the pivotal role in promoting inflammation and joint destruction. Treatment…Abstract Number: 1337 • 2016 ACR/ARHP Annual Meeting
Effectiveness of Certolizumab Pegol in Patients with Uveitis Refractory to Other Tumor Necrosis Factor Inhibitors. Report of 22 Cases
Background/Purpose: Refractory uveitis may requiere the use of biological therapy, especially tumour necrosis factors inhibitors (TNFi), being the most currently used infliximab and adalimumab. However,…Abstract Number: 1730 • 2016 ACR/ARHP Annual Meeting
Disease Progression Among Non-Achievers of Minimal Disease Activity in Psa Patients Treated with Infliximab or Golimumab
Background/Purpose : Early achievement of minimal disease activity (MDA) is recommended as a valid treat-to-target approach in psoriatic arthritis (PsA). The purpose of the current…Abstract Number: 2866 • 2015 ACR/ARHP Annual Meeting
Effectiveness and Safety of Golimumab in the Treatment of Psoriatic Arthritis over a 12 Month Period
Background/Purpose: The efficacy and tolerability of golimumab (GLM) in patients with psoriatic arthritis (PsA) has been demonstrated in several controlled clinical trials. Longitudinal observational studies…Abstract Number: 2744 • 2015 ACR/ARHP Annual Meeting
What Is the Treatment Durability and Safety Profile of Rheumatoid Arthritis Patients Treated with Infliximab Plus Methotrexate and/or Leflunomide? an Analysis from a Real-World Registry
Background/Purpose: Clinical trials of anti-TNF therapies have shown that concurrent methotrexate (MTX) therapy enhances the efficacy of TNF inhibitors. A scarcity of data exists on…Abstract Number: 1302 • 2015 ACR/ARHP Annual Meeting
Inflammation Signs on Magnetic Resonance Imaging in Chronic or Recurrent Gonarthritis Treated with Intra-Articular Infliximab or Corticosteroids
Background/Purpose: To evaluate synovial inflammation on magnetic resonance imaging (MRI) before treatment and changes after treatment with intra-articular (i.a.) infliximab (IFX) or methylprednisolone (MP) injections…Abstract Number: 1273 • 2015 ACR/ARHP Annual Meeting
Uptake of the First Biosimilar Infliximab Since Its Approval in South Korea
Background/Purpose: Development of tumor necrosis factor (TNF) inhibitors has been a major advance in treatment of systemic inflammatory diseases, such as rheumatoid arthritis. While TNF…Abstract Number: 599 • 2015 ACR/ARHP Annual Meeting
An Examination of Dose Escalation Among Remicade (infliximab) Users in a US RA Registry
Background/Purpose: Limited data are available about infliximab(IFX) dose escalation. This analysis examines the frequency of dose escalation among IFX patients using data from the US…Abstract Number: 595 • 2015 ACR/ARHP Annual Meeting
Discovery of Serum Protein Biomarkers of Response to Adalimumab in Rheumatoid Arthritis and Their Relationship to Biomarkers of Response to Infliximab
Background/Purpose: Biomarkers of response to treatment in rheumatoid arthritis (RA) are sorely needed given the large inter-individual variability in efficacy of the available drugs. However,…Abstract Number: 2763 • 2014 ACR/ARHP Annual Meeting
Long-Term Outcome of Chronic Progressive Neurological Manifestations in Behcet’s Disease
Background/Purpose: Chronic progressive neurological manifestations in Behcet's disease (BD) is characterized by progressive deterioration leading to disability either with or without a history of previous…Abstract Number: 2496 • 2014 ACR/ARHP Annual Meeting
Predictors of ACR/EULAR Boolean and SDAI Remission in Patients with Established Rheumatoid Arthritis Treated with Anti-TNF: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada
Background/Purpose Early achievement of remission is associated with improved clinical, functional and radiographic outcomes1. Recent recommendations of the Canadian Rheumatology Association dictate that treatment target…